# Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

> **NCT04506905** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 63 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Elpipodect
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04506905
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-28
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-03-22
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04506905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04506905, "Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04506905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*